Oral Immunization with rVSV Bivalent Vaccine Elicits Protective Immune Responses, Including ADCC, against Both SARS-CoV-2 and Influenza A Viruses

Thumbnail image

Download files

Language of the publication
English
Date
2023-08-23
Type
Article
Author(s)
  • Ouyang, Maggie Jing
  • Ao, Zhujun
  • Olukitibi, Titus A.
  • Lawrynuik, Peter
  • Shieh, Christopher
  • Yao, Xiaojian
  • Kobasa, Darwyn
  • Fowke, Keith R.
  • Kung, Sam K. P.
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)

Abstract

COVID-19 and influenza both cause enormous disease burdens, and vaccines are the primary measures for their control. Since these viral diseases are transmitted through the mucosal surface of the respiratory tract, developing an effective and convenient mucosal vaccine should be a high priority. We previously reported a recombinant vesicular stomatitis virus (rVSV)-based bivalent vaccine (v-EM2/SPΔC1(Delta)) that protects animals from both SARS-CoV-2 and influenza viruses via intramuscular and intranasal immunization. Here, we further investigated the immune response induced by oral immunization with this vaccine and its protective efficacy in mice. The results demonstrated that the oral delivery, like the intranasal route, elicited strong and protective systemic immune responses against SARS-CoV-2 and influenza A virus. This included high levels of neutralizing antibodies (NAbs) against SARS-CoV-2, as well as strong anti-SARS-CoV-2 spike protein (SP) antibody-dependent cellular cytotoxicity (ADCC) and anti-influenza M2 ADCC responses in mice sera. Furthermore, it provided efficient protection against challenge with influenza H1N1 virus in a mouse model, with a 100% survival rate and a significantly low lung viral load of influenza virus. All these findings provide substantial evidence for the effectiveness of oral immunization with the rVSV bivalent vaccine.

Subject

  • Health

Keywords

  • ADCC activity,
  • Covid-19,
  • SARS-CoV-2,
  • VSV vector,
  • bivalent vaccine,
  • influenza virus,
  • neutralizing antibody,
  • oral immunization,
  • vesicular stomatitis virus (VSV)

Rights

Peer review

Yes

Open access level

Gold

Identifiers

PubMed ID
37766083
ISSN
2076-393x
Other
PMC10534613

Article

Journal title
Vaccines (Basel)
Journal volume
11
Journal issue
9
Article number
1404

Citation(s)

Ouyang, M. J., Ao, Z., Olukitibi, T. A., Lawrynuik, P., Shieh, C., Kung, S. K. P., Fowke, K. R., Kobasa, D., & Yao, X. (2023). Oral Immunization with rVSV Bivalent Vaccine Elicits Protective Immune Responses, Including ADCC, against Both SARS-CoV-2 and Influenza A Viruses. Vaccines, 11(9), 1404. https://doi.org/10.3390/vaccines11091404

Download(s)

URI

Collection(s)

Communicable diseases

Full item page

Full item page

Page details

Date modified: